Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tropifexor PK in Hepatic Impairment
NCT03681457Phase 1Completed
- Sponsor
- Novartis
- Start
- Sep 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tropifexor in non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Novartis. Primary endpoints: Maximum Plasma Concentration up to 8 days, Time to Maximum Plasma Concentration up to 8 days and 5 more. Started Sep 2018; status: completed.
02
Drugs
tropifexor
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03681457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681457.